Edgewise Therapeuticsの空売り状況は、投資家がEdgewise Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Edgewise Therapeutics (NASDAQ:EWTX) 株価情報, 空売り情報

Edgewise Therapeutics

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics Inc

HC Wainwright &amp; Co. analyst Yi Chen maintains Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) with a Buy and raises the price target from $11 to $12.

News

Price Target

Analyst Ratings

SRTS

HC Wainwright & Co. Maintains Buy on Sensus Healthcare, Raises Price Target to $12

On Friday, February 7, U.S. markets closed lower after Trump announced plans for reciprocal tariffs amid weak jobs data and declining consumer sentiment. Despite early struggles, strong earnings provided some support. Consumer sentiment hit a seven-month low, inflation expectations surged, and job growth slowed, reinforcing expectations that the Fed will delay rate cuts until June.
The University of Michigan reported a sharp rise in inflation expectations, with the one-year outlook hitting 4.3%, the highest since November 2023. February&#8217;s jobs report showed mixed results: job growth slowed, but unemployment dropped more than expected, and wages surged.
All S&amp;P 500 sectors ended in the red, led by losses in communication services, consumer discretionary, and materials stocks.
The Dow Jones Industrial Average was down 0.99% and closed at 44,303.40, the S&amp;P 500 closed lower by 0.95% at 6,025.99, and the Nasdaq Composite fell 1.36% to finish at 19,523.40.
Aisa Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 closed lower by 0.12% at 38,770.50, led by losses in the Glass, Retail and Real Estate sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 declined 0.34% to 8,482.80, led by losses in the IT, Telecoms Services and Materials sectors.</li>
<li>India&#8217;s Nifty 50 closed lower by 0.78% at 23,376.05, and Nifty 500 slid 1.32%, closing at 21,360.55, led by losses in the Real Estate, Metals, and Consumer Durables sectors.</li>
<li>China&#8217;s Shanghai Composite rose 0.56% and closed at 3,322.17, and Shanghai Shenzhen CSI 300 was up 0.21% at 3,901.06.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session higher by 1.84% at 21,521.98.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was up 0.37%.</li>
<li>Germany&#8217;s DAX rose 0.31%.</li>
<li>France&#8217;s CAC gained 0.26%.</li>
<li>U.K.&#8217;s FTSE index 100 traded higher by 0.47%</li>
<li>European stocks opened higher on Monday despite Trump&#8217;s new tariff announcement. Markets remain optimistic amid strong earnings growth, cheap valuations, and hopes for ECB easing. Nokia appointed Justin Hotard as its new CEO.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 1.17% at $71.81/bbl, and Brent was up 1.15% at $75.50/bbl.</li>
<li>Oil prices rose, rebounding from last week&#8217;s losses amid trade war concerns. Sanctions on Russia and Iran add upside risks, but analysts expect oil to trade lower, with Brent forecasted at $60-$65 per barrel in late 2025.</li>
<li>Natural Gas gained 3.35% to $3.420.</li>
<li>Gold was trading higher by 1.46% at $2,930.21, Silver was up 0.95% to $32.750, and Copper rose 0.69% to $4.6200.</li>
<li>Gold hit record highs as Trump&#8217;s new tariffs fueled safe-haven demand. Markets remain cautious over potential trade war escalation, while strong U.S. inflation data and high interest rates could limit further gold gains.</li>
</ul>
U.S. Futures at 05:30 AM ET
<ul>
<li>Dow futures were up 0.28%, S&amp;P 500 futures gained 0.40%, and Nasdaq 100 futures rose 0.62%.</li>
<li>U.S. stock futures rose, led by steelmakers after Trump announced new tariffs. Investors remain cautious but less reactive to trade moves.</li>
</ul>
Forex at 05:30 AM ET
The U.S. Dollar Index gained 0.10% to 108.15, USD/JPY was up 0.52% to 152.19, and USD/AUD fell 0.14% to 1.5921.
Image via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Advances, Gold Hits Record High On Safe-Haven Demand - Global Markets Today While US Slept

Needham analyst Mike Cikos reiterates Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Buy and maintains $50 price target.

Reiteration

TENB

Needham Reiterates Buy on Tenable Holdings, Maintains $50 Price Target

Jones Trading analyst Jason Weaver maintains Alpine Income Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Buy and maintains $22 price target.

PINE

Jones Trading Maintains Buy on Alpine Income Prop Trust, Maintains $22 Price Target

B of A Securities analyst John Murphy upgrades Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Underperform to Neutral and raises the price target from $12 to $19.

Upgrades

MBLY

B of A Securities Upgrades Mobileye Global to Neutral, Raises Price Target to $19

Needham analyst Matt Dezort reiterates Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) from Hold to Hold.

QLYS

Needham Reiterates Hold on Qualysto Hold

Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) just disclosed its Q1 earnings on Monday, February 10, 2025 at 06:00 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Edgewell Personal Care missed estimated earnings by -42.0%, reporting an EPS of $0.07 versus an estimate of $0.12.
Revenue was down $10.50 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.05 in the last quarter, resulting in a 1.0% drop share price change the following day.
Here's a look at Edgewell Personal Care's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.67</td>
<td>1.01</td>
<td>0.72</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.72</td>
<td>1.22</td>
<td>0.88</td>
<td>0.24</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>535.23M</td>
<td>651.28M</td>
<td>606.45M</td>
<td>481.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>517.60M</td>
<td>647.80M</td>
<td>599.40M</td>
<td>488.90M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Edgewell Personal Care management provided guidance for FY 2025, expecting earnings between $3.15 and $3.15 per share.
To track all earnings releases for Edgewell Personal Care <a href="https://www.benzinga.com/quote/EPC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Edgewell Personal Care Earnings Report: Q1 Overview

The Q4 earnings report for CNA Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>) was released on Monday, February 10, 2025 at 06:00 AM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
CNA Financial beat estimated earnings by 3.0%, reporting an EPS of $1.25 versus an estimate of $1.21.
Revenue was up $182.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.01 in the previous quarter, leading to a 1.0% increase share price change the next day.
Here's a look at CNA Financial's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.07</td>
<td>1.23</td>
<td>1.39</td>
<td>1.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.08</td>
<td>1.19</td>
<td>1.30</td>
<td>1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.57B</td>
<td>3.55B</td>
<td>3.00B</td>
<td>2.95B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.62B</td>
<td>3.52B</td>
<td>3.44B</td>
<td>3.51B</td>
</tr>
</tbody>
</table>

To track all earnings releases for CNA Financial <a href="https://www.benzinga.com/quote/CNA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: CNA Financial Q4

Needham analyst Chris Pierce reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Hold to Hold.

TSLA

Needham Reiterates Hold on Teslato Hold

Needham analyst Scott Berg reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and maintains $400 price target.

Needham Reiterates Buy on Salesforce, Maintains $400 Price Target

Shiseido Co Sees FY2025 Sales JPY 995,000

Guidance

SSDOY

Shiseido Co Sees FY2025 Sales JPY 995,000

OMRON (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OMRNY#OTC">OMRNY</a>) reported quarterly earnings of $0.35 per share. This is a 473.77 percent increase over earnings of $0.06 per share from the same period last year. The company reported $1.35 billion in sales this quarter. This is a 4.06 percent decrease over sales of $1.40 billion the same period last year.

OMRNY

OMRON Q3 EPS $0.35 Up From $0.06 YoY, Sales $1.35B Down From $1.40B YoY

CNA Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.21 by 3.31 percent. This is a 6.02 percent decrease over earnings of $1.33 per share from the same period last year. The company reported quarterly sales of $3.69 billion which beat the analyst consensus estimate of $3.62 billion by 1.91 percent. This is a 5.19 percent increase over sales of $3.51 billion the same period last year.

Earnings Beats

CNA Financial Q4 Adj $1.25 Beats $1.21 Estimate, Sales $3.69B Beat $3.62B Estimate

Sun Country Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) ("Sun Country Airlines") today announced the commencement of a proposed secondary public offering of 6,346,105 shares of its common stock by an affiliate of certain investment funds managed by affiliates of Apollo Global Management, Inc. (the "Selling Stockholder"), which represent all the remaining shares owned by the Selling Stockholder.
Sun Country Airlines is not selling any shares and will not receive any proceeds from the proposed offering.
In addition, Sun Country Airlines has authorized the purchase from the underwriters of approximately $10 million of shares of common stock that are the subject of the proposed offering at a price per share equal to the price at which the underwriters will purchase the shares from the Selling Stockholder in the proposed offering, subject to a maximum aggregate repurchase price of $10 million (the "Concurrent Share Repurchase"). Sun Country Airlines plans to fund the Concurrent Share Repurchase from existing cash on hand.

Offerings

Buybacks

SNCY

Sun Country Airlines Announces $10M Stock Buyback Amid Stock Offload Of 6.34M Shares By Selling Stockholders By Apollo Global Management

Shiseido Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSDOY#OTC">SSDOY</a>) reported quarterly losses of $(0.17) per share. This is a 950 percent decrease over earnings of $0.02 per share from the same period last year. The company reported $1.76 billion in sales this quarter. This is a 3.66 percent increase over sales of $1.70 billion the same period last year.

Shiseido Co Q4 EPS USD$(0.17) Down From USD$0.02 YoY, Sales USD$1.76B Up From USD$1.70B YoY

Nokia Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) revealed a change in leadership as its President and CEO, Pekka Lundmark, is set to step down from his role. His replacement, Justin Hotard, is set to assume the position of President and CEO on April 1, 2025.
Lundmark, who has guided the company since 2020, will officially <a target="_blank" href="https://www.nokia.com/about-us/news/releases/2025/02/10/inside-information-nokia-announces-a-leadership-transition-justin-hotard-appointed-as-successor-to-pekka-lundmark/" rel="noreferrer noopener">depart </a>on March 31, 2025. Lundmark will remain involved as an advisor to Hotard throughout the remainder of 2025.
Hotard has more than 25 years of experience in the global tech industry, including leadership roles at prominent companies such as Intel Corp, Hewlett Packard Enterprise Co, and NCR Corporation.
Currently, he heads Intel&#8217;s Data Center &amp; AI Group, driving innovation, technological leadership, and strategies focused on growth.
Hotard will be based at Nokia&#8217;s headquarters in Espoo, Finland.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43563232/software-company-solarwinds-to-go-private-in-44b-deal-stocks-skyrocket" rel="noreferrer noopener">Software Company SolarWinds Agrees To Go Private In $4.4B Deal</a>
The leadership change follows a period of significant transformation at Nokia under Lundmark&#8217;s guidance, as the company worked to solidify its standing in the tech sector.
&#8220;Pekka joined at a difficult time in Nokia&#8217;s history. Under his tenure, Nokia has re-established its technology leadership in 5G radio networks and built a strong position in cloud-native core networks. Network Infrastructure has delivered growth and significant profit improvement, and Nokia has secured the longevity of its patent licensing business,&#8221; said Chair of Nokia&#8217;s Board of Directors, Sari Baldauf.
&#8220;I am delighted to welcome Justin to Nokia. He has a strong track record of accelerating growth in technology companies along with vast expertise in AI and data center markets, which are critical areas for Nokia&#8217;s future growth.&#8221;
Last month, Nokia reported net sales growth of 10% year-on-year to 5.98 billion euros ($6.39 billion) in the fourth-quarter, beating the consensus estimate of $6.17 billion, indicating a rebound in demand from communication service providers, <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43336863/nokia-q4-earnings-beats-estimates-strong-growth-network-cloud-boosts-profitability" rel="noreferrer noopener">particularly in North America</a>.
Established in 1865, Nokia is a prominent player in the telecommunications and consumer electronics sectors, focusing on mobile networks, software, and tech solutions.
Price Action: NOK shares closed higher by 0.42% at $4.81 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43566749/spire-global-lands-72m-contract-for-canadian-wildfire-detection-stock-jumps" target="_blank" rel="noreferrer noopener">Spire Global Lands ~$50M Contract For Canadian Wildfire Detection</a></li>
</ul>

Equities

Management

Tech

General

INTC

Nokia Taps Intel's AI Executive As New CEO - Details

ORIX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IX#NYSE">IX</a>) reported quarterly earnings of $2.56 per share which missed the analyst consensus estimate of $2.64 by 3.14 percent. This is a 3.87 percent decrease over earnings of $2.66 per share from the same period last year. The company reported $4.930 billion in sales this quarter. This is a 7.41 percent increase over sales of $4.590 billion the same period last year.

Earnings Misses

ORIX Q3 2024 GAAP EPS $2.56 Misses $2.64 Estimate, Sales $4.930B Up From $4.590B YoY

FreeCast and Foxx Development are announcing a new distribution agreement, bringing FreeCast's free streaming app to hundreds of thousands of smartphones and tablets. The FreeCast app is a one-stop source for live and on-demand video content, integrating hundreds of streaming apps into one easy-to-use platform. With FreeCast, consumers can find all the content they want to watch across different sources and providers for the lowest possible price.
Foxx Development is a consumer electronics and integrated Internet-of-Things (IoT) solution company. With robust research and development capabilities, it currently sells a diverse range of products including mobile phones, tablets and other consumer electronics devices throughout the United States. Foxx Development is a device provider for the National Lifeline Program, a federally funded program providing smartphones and wireless service to low-income consumers, with which FreeCast has extensive experience.

FCST

FOXX

FreeCast Teams Up With Foxx Development to Expand Free Streaming Access on Smartphones and Tablets

Shares of BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) rose sharply in pre-<a href="https://www.benzinga.com/quote/BP">market trading.</a>
The Wall Street Journal reported Sunday that Elliott Management has built a stake in BP and will push for transformational changes.
BP shares jumped 6% to $34.20 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Patriot National Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNBK#NASDAQ">PNBK</a>) gained 70.6% to $2.44 in pre-market trading after falling over 3% on Friday.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) rose 51% to $0.5020 in pre-market trading after falling around 4% on Friday.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 43.3% to $0.5953 in pre-market trading after jumping 124% on Friday.</li>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) gained 32.1% to $0.0795 in pre-market trading after dipping over 28% on Friday.</li>
<li>Yoshiharu Global Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) shares jumped 24.4% to $8.20 in pre-market trading after jumping 34% on Friday.</li>
<li>Microbot Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) gained 20% to $3.06 after surging around 18% on Friday.</li>
<li>Solid Biosciences Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares climbed 19.1% to $3.43 in pre-market trading after dipping 8% on Friday.</li>
<li>Satellogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) gained 13.6% to $4.19 in pre-market trading after climbing 10% on Friday.</li>
<li>Century Aluminum Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) gained 9.4% to $20.44 in pre-market.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Fennec Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) shares fell 54.8% to $3.00 in pre-market trading.</li>
<li>Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) dipped 54.5% to $3.54 in pre-market trading after the company issued an update on BEACON-IPF, a Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) fell 32.7% to $0.2550 in today's pre-market trading after gaining over 11% on Friday.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares fell 25.4% to $0.4701 in pre-market trading after gaining 5% on Friday.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) shares tumbled 25.2% to $40.75 in pre-market trading. Semtech shares fell around 10% on Friday after Baird cut its price target on the stock from $80 to $60.</li>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) declined 20.2% to $0.91 in pre-market trading after falling more than 5% on Friday.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) fell 19.6% to $11.21 in pre-market trading. Replimune announced inducement grants under Nasdaq Listing Rule 5635(c)(4).</li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 9.5% to $12.11 in pre-market trading. Maze Therapeutics shares gained around 3% on Friday after the company announced that the first patient has been dosed in the company&#8217;s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease.</li>
<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) fell 6.6% to $33.00 in pre-market trading.</li>
<li>The Manitowoc Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTW#NYSE">MTW</a>) shares dipped 6.4% to $9.12 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

CENX

DOGZ

FENC

MAZE

MBOT

MGOL

MYNA

ORIS

PLRX

PNBK

PSIG

REPL

SATL

SLDB

SMTC

STBX

YOSH

Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

U.S. GoldMining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USGO#NASDAQ">USGO</a>) ("U.S. GoldMining"&nbsp;or the "Company") is&nbsp;pleased to announce new assay results from the 2024 confirmatory diamond core drilling program completed at the Whistler Gold-Copper Project (the "Project") in Alaska, U.S.A.
The results reported in this news release highlight WH24-05, which was drilled adjacent to the Raintree West Deposit (the "Raintree Deposit"). The drilling intercepted multiple zones of high-grade gold and silver polymetallic mineralization approximately 500 meters south of any prior drilling at the deposit.
Selected Highlights:
<ul>
<li>Main Zone composite intercept of 138.0&nbsp;meters (m) at&nbsp;0.99 grams per tonne (g/t) gold equivalent (AuEq)&#x2A;&nbsp;comprising 0.89&nbsp;g/t gold (Au) and 0.05 percent (%) copper (Cu), plus 17.57 g/t silver (Ag), 0.44% lead (Pb) and 0.95% zinc (Zn) (elevated Ag, Pb and Zn grades are excluded in the AuEq calculations), from 635.0 m to 773.0 m down hole.</li>
<li>Including higher-grade individual intercepts:
<ul>
<li>26 m at 1.48 g/t AuEq&nbsp;(1.36 g/t Au, 0.06% Cu) plus 15.38 g/t Ag, 0.69% Pb and 1.61% Zn</li>
<li>34 m at 1.65 g/t AuEq&nbsp;(1.49 g/t Au, 0.08% Cu) plus 19.95 g/t Ag, 0.81% Pb and 1.35% Zn</li>
<li>18 m at 1.93 g/t AuEq&nbsp;(1.70 g/t Au, 0.13% Cu) plus 66.33 g/t Ag, 0.62% Pb and 1.84% Zn</li>
</ul>
</li>
<li>The drill intercept represents a relatively new style of&nbsp;mineralization - high-grade gold and silver polymetallic veins - with only one other intercept previously drilled at the Raintree Deposit:</li>
<li>This new discovery validates the Company's exploration strategy of exploring the Project to maximize its resource potential. Additional follow-up drilling is planned this coming summer.</li>
</ul>

USGO

US GoldMining Uncovers High-Grade Gold and Silver at Whistler Project in Alaska

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on EWTX stock, giving a Buy rating yesterday. Tessa Romero's rating is based o...

Buy Rating for Edgewise Therapeutics Driven by Promising CANYON Trial Results

Evercore ISI analyst Cory Kasimov raised the firm's price target on Edgewise Therapeutics (EWTX) to $50 from $45 and keeps an Outperform rating on ...

Edgewise Therapeutics price target raised to $50 from $45 at Evercore ISI

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR – Research Report), Edgewise ...

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Edgewise Therapeutics (EWTX) and Avadel Pharmaceuticals (AVDL)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company's shares...

Truist Financial Remains a Buy on Edgewise Therapeutics (EWTX)

Paul Matteis, an analyst from Stifel Nicolaus, has initiated a new Hold rating on Edgewise Therapeutics (EWTX). Paul Matteis has given his Hold rat...

Cautious Hold Rating for Edgewise Therapeutics Amid Uncertain Differentiation and Efficacy

Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has "very inter...

Edgewise Therapeutics initiated with a Hold at Stifel

Edgewise Therapeutics ( ($EWTX) ) just unveiled an update. On January 8, 2025, Edgewise Therapeutics announced the promotion of Behrad Derakhshan t...

Edgewise Therapeutics Promotes Derakhshan to COO Role

Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup

Baron Health Care Fund Q4 2024 Shareholder Letter

ACLX

ARGNF

ARGX

AVDL

AZNCF

BCAP

BROE

CYTK

EWTX

GKOS

ISRG

NTRA

RDNT

REGN

VRTX

Press Releases

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Arvinas

Axsome Therapeutics

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Edgewise Therapeutics

空売り

Edgewise Therapeutics (NASDAQ:EWTX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル